Eli Lilly leads GLP-1 market with $1.21T value; Novo Nordisk aims recovery despite stagnant growth.

Eli Lilly has outpaced Novo Nordisk in the GLP-1, obesity, and Type 2 Diabetes market, achieving a $1.21 trillion valuation. While Novo Nordisk's share price has fallen back after earlier gains and revenue growth remains flat, its management's strategic reset and pipeline developments have led to a Buy rating upgrade. Eli Lilly's strong pipeline, market momentum, and manufacturing capabilities position it to potentially exceed $100 billion in annual revenue soon. Despite risks and declining revenues, Novo Nordisk's oral GLP-1 advantage and strategic adjustments provide a credible path for long-term recovery.

Novo Nordisk trades at USD 38.67 with a 1.18% decline as of Oct 28, 2026 05:02 WIB on Pluang. Eli Lilly is priced at USD 1,283.00, up 0.30%, reflecting strong investor interest with 92% buy orders. Novo Nordisk's market cap stands at $172.48B, while Eli Lilly's is $1.14T, showing a significant size gap between the two.